Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive
research. Nowadays, only symptomatic treatments exist for this disease, all trying to …

Alzheimer's disease (AD) is the most common neurodegenerative disease, with cognitive
decline as the primary clinical feature. According to epidemiological statistics, 50 million …

The use of field-Effect-Transistor (FET) type biosensing arrangements has been highlighted
by researchers in the field of early biomarker detection and drug screening. Their non …

There is growing evidence that excessive microglial phagocytosis of neurons and synapses
contributes to multiple brain pathologies. RNA‐seq and genome‐wide association (GWAS) …

Curcumin, a yellow-colored molecule derived from the rhizome of Curcuma longa, has been
identified as the bioactive compound responsible for numerous pharmacological activities of …

Alzheimer's disease (AD), a common neurodegenerative disease in the elderly and the most
prevalent cause of dementia, is characterized by progressive cognitive impairment. The …

The adaptive immune system and associated inflammation are vital in surveillance and host
protection against internal and external threats, but can secondarily damage host tissues …

Triggering receptor expressed on myeloid cells 2 (TREM2) plays crucial roles in Alzheimer's
disease (AD) by regulating microglia migration toward, and phagocytosis of oligomeric …

Aging is broadly defined as the functional decline that occurs in all body systems. The
accumulation of senescent cells is considered a hallmark of aging and thought to contribute …

Despite all scientific efforts and many protracted and expensive clinical trials, no new drug
has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed …